Concepts (112)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| MicroRNAs | 8 | 2023 | 697 | 0.840 |
Why?
|
| Lung Neoplasms | 6 | 2024 | 696 | 0.710 |
Why?
|
| Kidney Neoplasms | 5 | 2023 | 166 | 0.700 |
Why?
|
| Urethral Stricture | 4 | 2023 | 70 | 0.630 |
Why?
|
| Carcinoma, Renal Cell | 4 | 2023 | 108 | 0.600 |
Why?
|
| Lichen Sclerosus et Atrophicus | 4 | 2023 | 20 | 0.570 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2024 | 175 | 0.350 |
Why?
|
| Gene Expression | 2 | 2026 | 851 | 0.330 |
Why?
|
| Adenocarcinoma | 2 | 2024 | 356 | 0.320 |
Why?
|
| Gene Expression Profiling | 7 | 2026 | 783 | 0.300 |
Why?
|
| Penile Induration | 1 | 2026 | 6 | 0.240 |
Why?
|
| Penis | 1 | 2026 | 38 | 0.240 |
Why?
|
| Sequence Analysis, RNA | 2 | 2026 | 180 | 0.210 |
Why?
|
| Urologic Surgical Procedures, Male | 2 | 2021 | 52 | 0.200 |
Why?
|
| Neoplasm Staging | 5 | 2024 | 529 | 0.200 |
Why?
|
| Urethra | 2 | 2021 | 76 | 0.190 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2023 | 106 | 0.180 |
Why?
|
| Adenocarcinoma in Situ | 1 | 2021 | 5 | 0.170 |
Why?
|
| N-Acetylglucosaminyltransferases | 1 | 2021 | 8 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2022 | 259 | 0.160 |
Why?
|
| Virus Internalization | 1 | 2021 | 90 | 0.160 |
Why?
|
| Single-Cell Analysis | 1 | 2021 | 122 | 0.160 |
Why?
|
| Bariatric Surgery | 1 | 2020 | 63 | 0.150 |
Why?
|
| Obesity, Morbid | 1 | 2020 | 97 | 0.150 |
Why?
|
| Ureteral Neoplasms | 1 | 2018 | 8 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 1 | 2021 | 266 | 0.140 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2018 | 43 | 0.140 |
Why?
|
| Humans | 20 | 2026 | 64283 | 0.130 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2024 | 1669 | 0.130 |
Why?
|
| Clinical Decision-Making | 1 | 2018 | 163 | 0.130 |
Why?
|
| Middle Aged | 10 | 2026 | 17921 | 0.130 |
Why?
|
| Aged | 9 | 2026 | 14662 | 0.130 |
Why?
|
| Biomarkers, Tumor | 1 | 2020 | 512 | 0.130 |
Why?
|
| Prognosis | 4 | 2022 | 1769 | 0.130 |
Why?
|
| Dasatinib | 1 | 2016 | 5 | 0.120 |
Why?
|
| Male | 12 | 2026 | 30322 | 0.120 |
Why?
|
| Cholangiocarcinoma | 1 | 2016 | 34 | 0.120 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2016 | 26 | 0.120 |
Why?
|
| src-Family Kinases | 1 | 2016 | 64 | 0.120 |
Why?
|
| Neoplasm Invasiveness | 3 | 2022 | 279 | 0.120 |
Why?
|
| Neoplasm Grading | 3 | 2021 | 91 | 0.120 |
Why?
|
| Early Detection of Cancer | 3 | 2024 | 321 | 0.110 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 202 | 0.110 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 709 | 0.100 |
Why?
|
| Retrospective Studies | 5 | 2022 | 6740 | 0.090 |
Why?
|
| Cell Proliferation | 3 | 2023 | 1002 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2023 | 358 | 0.080 |
Why?
|
| Female | 9 | 2024 | 33382 | 0.080 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2023 | 534 | 0.070 |
Why?
|
| Nephrectomy | 2 | 2020 | 93 | 0.070 |
Why?
|
| Mutation | 1 | 2016 | 2633 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2020 | 423 | 0.070 |
Why?
|
| Adult | 5 | 2026 | 17134 | 0.070 |
Why?
|
| Biopsy | 2 | 2019 | 449 | 0.060 |
Why?
|
| Kidney | 2 | 2020 | 455 | 0.060 |
Why?
|
| Cluster Analysis | 2 | 2017 | 263 | 0.060 |
Why?
|
| Cell Line, Tumor | 2 | 2023 | 1496 | 0.060 |
Why?
|
| Aged, 80 and over | 3 | 2021 | 5528 | 0.060 |
Why?
|
| Erectile Dysfunction | 1 | 2026 | 28 | 0.060 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 2482 | 0.050 |
Why?
|
| Disease Progression | 2 | 2020 | 1176 | 0.050 |
Why?
|
| Risk Assessment | 2 | 2021 | 2048 | 0.050 |
Why?
|
| Biomarkers | 2 | 2019 | 1431 | 0.050 |
Why?
|
| Cohort Studies | 2 | 2021 | 2605 | 0.050 |
Why?
|
| Administration, Intravesical | 1 | 2023 | 13 | 0.050 |
Why?
|
| Constriction, Pathologic | 1 | 2023 | 132 | 0.050 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2022 | 45 | 0.050 |
Why?
|
| Bronchi | 1 | 2022 | 84 | 0.050 |
Why?
|
| Transcriptome | 1 | 2026 | 396 | 0.050 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2023 | 204 | 0.040 |
Why?
|
| Genetic Markers | 1 | 2021 | 130 | 0.040 |
Why?
|
| Homeodomain Proteins | 1 | 2023 | 272 | 0.040 |
Why?
|
| Cathepsin L | 1 | 2021 | 22 | 0.040 |
Why?
|
| Alveolar Epithelial Cells | 1 | 2021 | 9 | 0.040 |
Why?
|
| Datasets as Topic | 1 | 2021 | 28 | 0.040 |
Why?
|
| Cell Movement | 1 | 2023 | 466 | 0.040 |
Why?
|
| Tumor Burden | 1 | 2021 | 73 | 0.040 |
Why?
|
| Respiratory System | 1 | 2021 | 48 | 0.040 |
Why?
|
| Demography | 1 | 2021 | 174 | 0.040 |
Why?
|
| Organ Specificity | 1 | 2021 | 196 | 0.040 |
Why?
|
| Immunotherapy | 1 | 2023 | 265 | 0.040 |
Why?
|
| Serine Endopeptidases | 1 | 2021 | 121 | 0.040 |
Why?
|
| Survival Analysis | 1 | 2021 | 587 | 0.040 |
Why?
|
| Tissue Array Analysis | 1 | 2019 | 37 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2019 | 67 | 0.040 |
Why?
|
| Mitosis | 1 | 2021 | 218 | 0.040 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2020 | 297 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2020 | 5696 | 0.040 |
Why?
|
| Transfection | 1 | 2021 | 696 | 0.040 |
Why?
|
| Reoperation | 1 | 2019 | 292 | 0.040 |
Why?
|
| Weight Loss | 1 | 2020 | 276 | 0.030 |
Why?
|
| Recurrence | 1 | 2019 | 652 | 0.030 |
Why?
|
| Smoking | 1 | 2022 | 861 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2021 | 856 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2019 | 901 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2017 | 64 | 0.030 |
Why?
|
| Predictive Value of Tests | 1 | 2020 | 1105 | 0.030 |
Why?
|
| RNA, Small Interfering | 1 | 2023 | 930 | 0.030 |
Why?
|
| Pilot Projects | 1 | 2020 | 1020 | 0.030 |
Why?
|
| Protein Biosynthesis | 1 | 2019 | 329 | 0.030 |
Why?
|
| Mice | 2 | 2023 | 11004 | 0.030 |
Why?
|
| Survival Rate | 1 | 2018 | 859 | 0.030 |
Why?
|
| Bile Duct Neoplasms | 1 | 2016 | 58 | 0.030 |
Why?
|
| Lung | 1 | 2021 | 964 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2016 | 195 | 0.030 |
Why?
|
| Inflammation | 1 | 2021 | 1163 | 0.030 |
Why?
|
| Sensitivity and Specificity | 1 | 2017 | 1164 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2019 | 3318 | 0.020 |
Why?
|
| Animals | 2 | 2023 | 20967 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2016 | 2238 | 0.020 |
Why?
|
| United States | 1 | 2021 | 7923 | 0.020 |
Why?
|
| Young Adult | 1 | 2017 | 4781 | 0.020 |
Why?
|